期刊文献+

颌下腺套细胞淋巴瘤病理特点分析

Study of clinical- pathological features for mantle cell lymphoma in submandibular gland
下载PDF
导出
摘要 目的探讨颌下腺套细胞淋巴瘤(MCL)的病理临床表现、免疫表型特征、在诊断及鉴别诊断中的意义。方法对1例颌下腺MCL行组织形态和免疫组化结果观察分析并结合文献归纳颌下腺MCL的病理特点。结果本例颌下腺经典型MCL由形态单一的小到中等大的肿瘤性淋巴细胞组成,弥漫排列,核形不规则,有的可见核裂,很像滤泡中心细胞,核分裂像易见,肿瘤细胞间散在无吞噬活性的组织细胞。间质见透明变性小血管。免疫组化:肿瘤细胞CD20(+),CD5(+),CD43(+),CyclinD1(+),bcl-2(+),CD3(-),CD10(-),bcl-6(-),CD23(-),CD21显示扩大不规则的滤泡树突细胞网(FDC网)。结论颌下腺套细胞淋巴瘤有其自身组织学特征,CyclinD1(+)有助于临床诊断。 Objective To study clinical- pathological and immunophenotypic features for mantle cell lymphoma in submandibular gland which can be used in the diagnosis and differential diagnosis. Methods To analyze morphology and immunohistochemitry of one case of mantle cell lymphoma in submandibular gland and to review literature. Results The classic mantle cell lymphoma of submandibular gland with diffuse pattern of growth is composed of monomorphous small to medium - sized ceils with slightly irregular nuclei which most closely resembled centrocytes. Large scattered epithelioid histiocytes with no tingible bodies and hyalinized venules are distinct. Mitoses are easily found. Immunostaining results for CDS, CD43, CD20, CyclinD1 and bcl - 2 are positive and negative for CD3, CD10, bcl - 6 and CD23. CD21 staining present large FDC network. Conclusion Mantle cell lymphoma of submandibular gland have distinct histological architectures and Cyclin D1 is specific immunohistochemistric staining for it.
出处 《大连医科大学学报》 CAS 2013年第5期477-480,共4页 Journal of Dalian Medical University
关键词 颌下腺 套细胞淋巴瘤 诊断 submandibular gland mantle cell lymphoma diagnosis
  • 相关文献

参考文献9

  • 1梅开勇,郝卓芳,叶子茵,林汉良,林素暇,苏祖兰.套细胞淋巴瘤临床病理特征及免疫表型分析[J].诊断病理学杂志,2013,20(5):275-278. 被引量:14
  • 2Swerdlow SH, Campo E, Harris NL, et al. World HealthOrganization Classification of Tumours, Pathology ofTumours of Haematopoietic and Lymphoid Tissues [ M ].4th edition. Lyon, France: IARC Press,2008 :229 -232.
  • 3Pilavaki M,Athanasiadou A, Iordanidis F, et al. Magneticresonance imaging with pathological correlation in a case ofmantle cell lymphoma of the parotid gland : a case report[J]. J Med Case Rep,2010,30(4) :99.
  • 4Triantafillidou K, Dimitrakopoulos J, Iordanidis F, et al.Extranodal non - hodgkin lymphomas of the oral cavity andmaxillofacial region : a clinical study of 58 cases and reviewof the literature [ J ]. J Oral Maxillofac Surg, 2012, 70(12):2776 -2785.
  • 5Weisenburger DD, Armitage JQ. Mantle cell lymphoma —an entity comes of age[ J]. Blood, 1996,87 ;4483 -4494.
  • 6Sander B. Mantle cell lymphoma: recent insights into path-ogenesis ,clinical variability, and new diagnostic markers[J]. Semin Diagn Pathol,2011 ,28(3) :245 -255.
  • 7Schrader C, Meusers P,Brittinger G, et al. Growth patternand distribution of follicular dendritic cells in mantle celllymphomas : a clinicopathological study of 96 patients [ J].Virchows Arch,2006,448(2) :151 -159.
  • 8Cheuk W, Yuen HK, Chan AC, et al. Ocular adnexallymphoma associated with IgG4 + chronic sclerosingdacryoadenitis : A previously undescribed complication ofIgG4 _ related sclerosing disease [ J ] . Am J Surg Pathol,2008,32:1159 -1167.
  • 9涂三芳,李玉华.复发难治B细胞性非霍奇金淋巴瘤的治疗进展[J].山东医药,2012,52(9):95-98. 被引量:11

二级参考文献26

  • 1Coiffier B.Rituximab in combination with CHOP improves survivalin elderly patients with aggressive non-Hodgkin’s lymphoma[J].Semin Oncol,2002,29(2 Suppl 6):18-22.
  • 2Shivakumar L,Armitage JO.Bcl-2 gene expression as a predictor ofoutcome in diffuse large B-cell lymphoma[J].Clin Lymphoma Mye-loma,2006,6(6):455-457.
  • 3Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICEas second-line therapy before autologous stem cell transplantation forrelapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684-3688.
  • 4El Gnaoui T,Dupuis J,Belhadj K,et al.Rituximab,gemcitabineand oxaliplatin:an effective salvage regimen for patients with re-lapsed or refractory B-cell lymphoma not candidates for high-dosetherapy[J].Ann Oncol,2007,18(8):1363-1368.
  • 5Emmanouilides C,Lill M,Telatar M,et al.Mitoxantrone/ifos-famide/etoposide salvage regimen with rituximab for in vivo purgingin patients with relapsed lymphoma[J].Clin Lymphoma,2002,3(2):111-116.
  • 6Appelbaum FR.Hematopoietic cell transplantation for non-Hodgkin’slymphoma:yesterday,today,and tomorrow[J].J Clin Oncol,2008,26(18):2927-2929.
  • 7Peniket AJ,Ruiz de Elvira MC,Taghipour G,et al.An EBMT reg-istry matched study of allogeneic stem cell transplants for lymphoma:allogeneic transplantation is associated with a lower relapse rate but ahigher procedure-related mortality rate than autologous transplanta-tion[J].Bone Marrow Transplant,2003,31(8):667-678.
  • 8Goy A,Bernstein SH,Kahl BS,et al.Bortezomib in patients withrelapsed or refractory mantle cell lymphoma:updated time-to-eventanalyses of the multicenter phase 2 PINNACLE study[J].Ann On-col,2009,20(3):520-525.
  • 9Rummel MJ,Al-Batran SE,Kim SZ,et al.Bendamustine plus rit-uximab is effective and has a favorable toxicity profile in the treat-ment of mantle cell and low-grade non-Hodgkin’s lymphoma[J].JClin Oncol,2005,23(15):3383-3389.
  • 10Weide R,Hess G,Koppler H,et al.High anti-lymphoma activityof bendamustine/mitoxantrone/rituximab in rituximab pretreated re-lapsed or refractory indolent lymphomas and mantle cell lymphomas.A multicenter phaseⅡstudy of the German Low Grade LymphomaStudy Group(GLSG)[J].Leuk Lymphoma,2007,48(7):1299-1306.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部